Home › Acute Lymphoblastic Leukemia › NCT05857969
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Advancing Personalized Treatment in Pediatric Oncology Through Functional Precision Medicine
Who can join
1 Day – 21 Years · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients aged 21 years or younger at the time of enrollment on this study of any gender, race or ethnicity. Subjects with suspected or confirmed diagnosis of recurrent or refractory cancer Subjects who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) Subjects willing to have a blood draw or buccal swab done for the purposes of genetic testing Subjects or their parents or legal guardians willing to sign informed consent Subjects aged 7 to 17 willing to sign assent Exclusion Criteria: * Subjects who do not have malignant tissue available and accessible The amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling. Patients with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.
About the study
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
What is being tested
- Functional Precision Medicine (device)
Sponsor: Florida International University · Participants: 65 · Started: Feb 22, 2023
Contact the study team
- Diana Azzam, PhD · Phone: 305-348-9043
- Lillian Garvin · Phone: 800-533-1792
Official record on ClinicalTrials.gov — NCT05857969
Locations in the U.S.
| Florida | Nicklaus Children's Hospital, Miami |
Conditions
- Acute Lymphoblastic Leukemia
- Interdigitating Dendritic Cell Sarcoma
- Chronic Myeloid Leukemia
- Cancer (all types)
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.